Clinical trial
Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors
NCT01226030 is registered in ClinicalTrials.gov with Beijing Protgen Biotechnology Development Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors
- Lead sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 30, 2009
- Completion date
- June 30, 2011
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors